Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

Condition(s) studied

Investigational drug(s) / intervention(s)

Open-Label Envudeucitinib: Open-Label ESK-001

Blinded Envudeucitinib: Blinded ESK-001 during Randomized Treatment Withdrawal Period

Placebo: Placebo during Randomized Treatment Withdrawal Period

Study summary

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are:

* How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis?
* Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis?

Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study.

Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis.

Patients must consent and agree to:

* ensure drug daily compliance until end of study or discontinuation.
* visit the clinic for checkups and assessments.
* provide blood and urine samples.

Eligibility

Primary outcome measure(s)

• To assess the long-term safety and tolerability of ESK-001 throughout the duration of the study — Approximately 4 years
  Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

Trial sites (268)

+ 228 more sites — see the full list on the official registry below.

More Alumis Inc trials in Germany

Other trials for the same condition